Novo Nordisk A/S (NVO) Hits New 12-Month Low at $45.36
Shares of Novo Nordisk A/S (NYSE:NVO) hit a new 52-week low during trading on Friday . The stock traded as low as $45.36 and last traded at $45.79, with a volume of 2,863,145 shares traded. The stock had previously closed at $46.34.
Several analysts have recently commented on the company. Morgan Stanley cut Novo Nordisk A/S from an “overweight” rating to an “equal weight” rating in a research report on Thursday. HSBC raised Novo Nordisk A/S from a “reduce” rating to a “hold” rating in a research report on Wednesday. Bank of America Corp. cut Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Monday, August 8th. Citigroup Inc. reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Wednesday, August 3rd. Finally, Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Monday, July 11th. Four equities research analysts have rated the stock with a hold rating, three have given a buy rating and two have given a strong buy rating to the stock. Novo Nordisk A/S currently has a consensus rating of “Buy” and a consensus price target of $63.50.
The stock has a market capitalization of $116.16 billion and a PE ratio of 21.27. The stock’s 50 day moving average price is $51.08 and its 200-day moving average price is $53.65.
The firm also recently announced a dividend, which was paid on Tuesday, August 23rd. Shareholders of record on Monday, August 15th were given a dividend of $0.326 per share. The ex-dividend date of this dividend was Thursday, August 11th.
Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.